Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma

[1]  C. Lian,et al.  Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity , 2017, Laboratory Investigation.

[2]  A. Wysong,et al.  Management of Skin Cancer in the High-Risk Patient , 2016, Current Treatment Options in Oncology.

[3]  Wei Zhang,et al.  Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells , 2016, Cellular Physiology and Biochemistry.

[4]  P. Bisen,et al.  Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  A. Maiorana,et al.  Survivin Modulates Squamous Cell Carcinoma-Derived Stem-Like Cell Proliferation, Viability and Tumor Formation in Vivo , 2016, International journal of molecular sciences.

[6]  Lan Liu,et al.  Overexpression of miR-214-3p in Esophageal Squamous Cancer Cells Enhances Sensitivity to Cisplatin by Targeting Survivin Directly and Indirectly Through CUG-BP1 , 2015, Oncogene.

[7]  J. Yun,et al.  YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines. , 2015, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[8]  Lan-Lan Wang,et al.  P16INK4A and survivin: Diagnostic and prognostic markers in cervical intraepithelial neoplasia and cervical squamous cell carcinoma. , 2015, Experimental and molecular pathology.

[9]  Xiaohang Zhao,et al.  YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice , 2015, Oncotarget.

[10]  Haitao Ma,et al.  Survivin over-expression is correlated with a poor prognosis in esophageal cancer patients. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[11]  A. Kulkarni,et al.  Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma , 2015, Cell Death and Disease.

[12]  J. Engelman,et al.  The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. , 2015, Cancer discovery.

[13]  S. Wheatley,et al.  Mitotic activity of survivin is regulated by acetylation at K129 , 2015, Cell cycle.

[14]  C. Rubini,et al.  Clinical and prognostic significance of survivin, AKT and VEGF in primary mucosal oral melanoma. , 2015, Anticancer research.

[15]  S. Tait,et al.  Mitochondrial apoptosis: killing cancer using the enemy within , 2015, British Journal of Cancer.

[16]  C. Day,et al.  IAPs: Modular regulators of cell signalling. , 2015, Seminars in cell & developmental biology.

[17]  Dario C Altieri.  Survivin - The inconvenient IAP. , 2015, Seminars in cell & developmental biology.

[18]  Z. Cai,et al.  Clinicopathological and Prognostic Significance of Survivin Expression in Patients with Oral Squamous Cell Carcinoma: Evidence from a Meta-Analysis , 2015, PloS one.

[19]  Z. Tao,et al.  Downregulation of Survivin by shRNA Inhibits Invasion and Enhances the Radiosensitivity of Laryngeal Squamous Cell Carcinoma , 2015, Cell Biochemistry and Biophysics.

[20]  S. Wheatley.  The Functional Repertoire of Survivin's Tails , 2015, Cell cycle.

[21]  Sang-Gu Hwang,et al.  Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation , 2014, Oncotarget.

[22]  Z. Tu,et al.  Survivin gene functions and relationships between expression and prognosis in patients with nasopharyngeal carcinoma. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[23]  M. Kosacka,et al.  Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma. , 2015, Advances in experimental medicine and biology.

[24]  C. Chung,et al.  Emerging biomarkers in head and neck cancer in the era of genomics , 2015, Nature Reviews Clinical Oncology.

[25]  D. Flieder,et al.  p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary , 2014, Head & neck.

[26]  M. Michaelis,et al.  A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[27]  H. Ertl,et al.  Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models , 2014, Molecular therapy. Nucleic acids.

[28]  Herb Chen,et al.  The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. , 2014, The Journal of surgical research.

[29]  D. Parmar,et al.  Expression of survivin mRNA in gallbladder cancer: a diagnostic and prognostic marker? , 2014, Tumor Biology.

[30]  L. R. Molife,et al.  Cancer therapeutics: Targeting the apoptotic pathway. , 2014, Critical reviews in oncology/hematology.

[31]  Kai-Ping Chang,et al.  Salivary Auto-Antibodies as Noninvasive Diagnostic Markers of Oral Cavity Squamous Cell Carcinoma , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[32]  G. Schneider,et al.  Survivin and YM155: how faithful is the liaison? , 2014, Biochimica et biophysica acta.

[33]  R. Hong,et al.  Significance of intracellular localization of survivin in cervical squamous cell lesions: Correlation with disease progression , 2014, Oncology letters.

[34]  P. Morandi,et al.  Expression of nuclear survivin in normal skin and squamous cell carcinoma: a possible role in tumour invasion , 2013, British Journal of Cancer.

[35]  J. Silke,et al.  IAP family of cell death and signaling regulators. , 2014, Methods in enzymology.

[36]  W. Westra,et al.  Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications , 2014, European Archives of Oto-Rhino-Laryngology.

[37]  M. Horinaka,et al.  A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. , 2013, International journal of oncology.

[38]  A. Santarelli,et al.  Detection Level of Salivary Survivin in Patients with OSCC , 2013 .

[39]  Jing-pu Yang,et al.  Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo. , 2013, International journal of clinical and experimental pathology.

[40]  Bei Liu,et al.  Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo , 2013, Oncology letters.

[41]  Qingyun Zhang,et al.  Sandwich ELISA for detecting urinary Survivin in bladder cancer. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[42]  P. Bisen,et al.  Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. , 2013, Biochimica et biophysica acta.

[43]  C. R. Leemans,et al.  Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients , 2013, Journal of Translational Medicine.

[44]  R. Kurzrock,et al.  Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. , 2013, Cancer treatment reviews.

[45]  G. Das,et al.  Sodium valproate potentiates staurosporine‐induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition , 2013, Journal of cellular biochemistry.

[46]  M. Trotter,et al.  Single-cell gene expression profiling reveals functional heterogeneity of undifferentiated human epidermal cells , 2013, Development.

[47]  E. Tirrò,et al.  Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs , 2013, Molecular Cancer Therapeutics.

[48]  B. Sitek,et al.  Loss of Survivin influences liver regeneration and is associated with impaired Aurora B function , 2013, Cell Death and Differentiation.

[49]  Li-Ping Ge,et al.  Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis , 2013, Clinical and Translational Oncology.

[50]  Jianjun Zhang,et al.  The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells , 2013, Clinical and Experimental Medicine.

[51]  Peng Zhang,et al.  Inhibition of lymphatic metastases by a survivin dominant-negative mutant. , 2013, Oncology research.

[52]  P. Bisen,et al.  Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression. , 2012, Current gene therapy.

[53]  M. Flentje,et al.  Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity. , 2012, Translational oncology.

[54]  Q. Xiao,et al.  Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation , 2012, British journal of biomedical science.

[55]  Jing Yang,et al.  The apoptotic effect and associated signalling of HSP90 inhibitor 17‐DMAG in hepatocellular carcinoma cells , 2012, Cell biology international.

[56]  Shigeki Kawabata,et al.  Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. , 2012, Biochemical and biophysical research communications.

[57]  A. Kulkarni,et al.  Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model , 2012, Clinical Cancer Research.

[58]  G. Giannini,et al.  Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors. , 2012, European journal of medicinal chemistry.

[59]  Shan Zhu,et al.  TSA‐induced JMJD2B downregulation is associated with cyclin B1‐dependent survivin degradation and apoptosis in LNCap cells , 2012, Journal of cellular biochemistry.

[60]  Shigeki Kawabata,et al.  Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin , 2012, Molecular & Cellular Proteomics.

[61]  J. Vose,et al.  A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma , 2012, Cancer.

[62]  D. Newton,et al.  The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response , 2012, Cancer Chemotherapy and Pharmacology.

[63]  Lin Xu,et al.  Prognostic Value of Survivin in Patients with Non-Small Cell Lung Carcinoma: A Systematic Review with Meta-Analysis , 2012, PloS one.

[64]  B. Wollenberg,et al.  Stem cells in squamous head and neck cancer. , 2012, Critical reviews in oncology/hematology.

[65]  M. P. Holloway,et al.  Histone Deacetylase 6 (HDAC6) Deacetylates Survivin for Its Nuclear Export in Breast Cancer* , 2012, The Journal of Biological Chemistry.

[66]  Mingqiang Kang,et al.  Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells , 2012, Molecular medicine reports.

[67]  Jiamu Du,et al.  Structural basis for recognition of H3T3ph and Smac/DIABLO N-terminal peptides by human Survivin. , 2012, Structure.

[68]  A. Marconi,et al.  Survivin: a dual player in healthy and diseased skin. , 2012, The Journal of investigative dermatology.

[69]  Shang Gao,et al.  Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma , 2011, Medical oncology.

[70]  Huanjie Shao,et al.  Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. , 2011, Biochemical pharmacology.

[71]  M. Brattain,et al.  Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor β (TGFβ) Receptor II Leading to Cancer Cell Death* , 2011, The Journal of Biological Chemistry.

[72]  Y. Surh,et al.  Ibulocydine Is a Novel Prodrug Cdk Inhibitor That Effectively Induces Apoptosis in Hepatocellular Carcinoma Cells* , 2011, The Journal of Biological Chemistry.

[73]  P. Holliger,et al.  Ribozyme-Catalyzed Transcription of an Active Ribozyme , 2011, Science.

[74]  M. Brownstein,et al.  Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy , 2011, International journal of cancer.

[75]  A. Yamaguchi,et al.  Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer , 2011, Cancer science.

[76]  M. Emmert-Buck,et al.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. , 2011, American journal of cancer research.

[77]  S. Achiraman,et al.  Survivin deficiency leads to imparalization of cytokinesis in cancer cells. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[78]  J. Węsierska‐Gądek,et al.  Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells. , 2011, Journal of experimental therapeutics & oncology.

[79]  U. Ghoshal,et al.  Role of Survivin Gene Promoter Polymorphism (−31G>C) in Susceptibility and Survival of Esophageal Cancer in Northern India , 2011, Annals of Surgical Oncology.

[80]  J. Liao,et al.  Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. , 2010, Blood.

[81]  Hongbing Shen,et al.  Prognostic Significance of Survivin Polymorphisms on Non-small Cell Lung Cancer Survival , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[82]  S. Mouhamad,et al.  Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel. , 2010, Current cancer drug targets.

[83]  I. da Silva,et al.  Survivin and Telomerase Expression in the Uterine Cervix of Women With Human Papillomavirus-Induced Lesions , 2010, International Journal of Gynecologic Cancer.

[84]  Sun Liping,et al.  Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. , 2010 .

[85]  P. Marks.  Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. , 2010, Biochimica et biophysica acta.

[86]  M. P. Holloway,et al.  Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic Activity* , 2010, The Journal of Biological Chemistry.

[87]  D. Altieri.  Survivin and IAP proteins in cell-death mechanisms. , 2010, The Biochemical journal.

[88]  P. Bisen,et al.  Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[89]  D Saur,et al.  Cross talk between stimulated NF-κB and the tumor suppressor p53 , 2010, Oncogene.

[90]  Zhou Jinsong,et al.  Adeno-Associated Virus Harboring Fusion Gene NT4-Ant-Shepherdin Induce Cell Death in Human Lung Cancer Cells , 2010, Cancer investigation.

[91]  J. Kanwar,et al.  Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells , 2010, Molecular Cancer.

[92]  Y. Kudo,et al.  Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. , 2010, Oral oncology.

[93]  Yan Shi,et al.  Expression of Elf-1 and survivin in non-small cell lung cancer and their relationship to intratumoral microvessel density. , 2010, Chinese journal of cancer.

[94]  K. Matsuno,et al.  Identification of a small-molecule inhibitor of the interaction between Survivin and Smac/DIABLO. , 2010, Biochemical and biophysical research communications.

[95]  S. Kim,et al.  Evaluation of survivin as a prognostic marker in oral squamous cell carcinoma. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[96]  Peng Zhang,et al.  Enhanced tumor radiosensitivity by a survivin dominant-negative mutant. , 2009, Oncology reports.

[97]  S. Takeno,et al.  Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[98]  Ying Wang,et al.  Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. , 2010, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[99]  P. Zatloukal,et al.  Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. , 2009, International journal of oncology.

[100]  G. Giaccone,et al.  Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  N. K. Sah,et al.  Detection of survivin and p53 in human oral cancer: Correlation with clinicopathologic findings , 2009, Head & neck.

[102]  H. Okada,et al.  Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice , 2009, Diabetologia.

[103]  L. Neckers,et al.  Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. , 2009, The Journal of clinical investigation.

[104]  Bin Wang,et al.  The Association Between the Survivin C-31G Polymorphism and Gastric Cancer Risk in a Chinese Population , 2009, Digestive Diseases and Sciences.

[105]  Long Yu,et al.  The evolution of BIR domain and its containing proteins , 2008, FEBS letters.

[106]  A. Tolcher,et al.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Alain C. Mita,et al.  Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics , 2008, Clinical Cancer Research.

[108]  J. Greenman,et al.  Genetic profile of head and neck squamous cell carcinoma: clinical implications , 2008, The Journal of Laryngology & Otology.

[109]  Jingde Zhu,et al.  Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. , 2008, Acta biochimica et biophysica Sinica.

[110]  J. Hauser,et al.  Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. , 2008, Cancer research.

[111]  Jing Zhao,et al.  A survivin double point mutant has potent inhibitory effect on the growth of hepatocellular cancer cells , 2008, Cancer biology & therapy.

[112]  S. Staibano,et al.  Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[113]  D. Altieri.  Survivin, cancer networks and pathway-directed drug discovery , 2008, Nature Reviews Cancer.

[114]  Xuejun Jiang,et al.  A Dimeric Smac/Diablo Peptide Directly Relieves Caspase-3 Inhibition by XIAP , 2007, Journal of Biological Chemistry.

[115]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[116]  J. Cleveland,et al.  Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. , 2007, Cancer research.

[117]  S. Porceddu,et al.  Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes , 2007, Head & neck.

[118]  J. Paul Robinson,et al.  Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells , 2007, Cancer biology & therapy.

[119]  D. Marchion,et al.  Development of histone deacetylase inhibitors for cancer treatment , 2007, Expert review of anticancer therapy.

[120]  D. Metzler,et al.  Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker , 2007, The Journal of pathology.

[121]  F. Végran,et al.  Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer , 2007, Oncogene.

[122]  N. K. Sah,et al.  Structural, functional and therapeutic biology of survivin. , 2006, Cancer letters.

[123]  A. Tolcher,et al.  Apoptosis: mechanisms and implications for cancer therapeutics , 2006, Targeted Oncology.

[124]  M. Andreeff,et al.  Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. , 2006, Journal of the National Cancer Institute.

[125]  S. Fukuda,et al.  Survivin, a cancer target with an emerging role in normal adult tissues , 2006, Molecular Cancer Therapeutics.

[126]  R. Stauber,et al.  Acetylation of Stat1 modulates NF-B activity , 2006 .

[127]  Jinlong Li,et al.  Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma , 2006, Cancer biology & therapy.

[128]  P. Bisen,et al.  Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene , 2006 .

[129]  Sandra Siegel,et al.  Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies , 2006, Leukemia & lymphoma.

[130]  A. Yılmaz,et al.  Correlation between survivin expression and prognosis in non-small cell lung cancer. , 2005, Respiratory medicine.

[131]  R. Stauber,et al.  Acetylation of Stat1 modulates NF-kappaB activity. , 2006, Genes & development.

[132]  M. Ueno,et al.  Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. , 2005, International journal of oncology.

[133]  S. Forsburg,et al.  Suppressors of Bir1p (Survivin) Identify Roles for the Chromosomal Passenger Protein Pic1p (INCENP) and the Replication Initiation Factor Psf2p in Chromosome Segregation , 2005, Molecular and Cellular Biology.

[134]  S. Egawa,et al.  Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo , 2005, The Prostate.

[135]  J. Sampath,et al.  Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. , 2005, Cancer research.

[136]  N. Curtin,et al.  Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation , 2005, Molecular Cancer Therapeutics.

[137]  F. Pezzetti,et al.  Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. , 2005, Cancer letters.

[138]  Q. Zhan,et al.  Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells , 2005, Cancer biology & therapy.

[139]  R. Park,et al.  Systemic Treatment with Tetra-O-Methyl Nordihydroguaiaretic Acid Suppresses the Growth of Human Xenograft Tumors , 2005, Clinical Cancer Research.

[140]  Nerea Martínez,et al.  Expression of the NF‐κB targets BCL2 and BIRC5/Survivin characterizes small B‐cell and aggressive B‐cell lymphomas, respectively , 2005, The Journal of pathology.

[141]  S. Hsue,et al.  Survivin expression is regulated by an epigenetic mechanism for DMBA-induced hamster buccal-pouch squamous-cell carcinomas. , 2005, Archives of oral biology.

[142]  G. Colombo,et al.  Rational design of shepherdin, a novel anticancer agent. , 2005, Cancer cell.

[143]  A. Chakravarti,et al.  Survivin mediates resistance to antiandrogen therapy in prostate cancer , 2005, Oncogene.

[144]  M. P. Holloway,et al.  Survivin splice variants regulate the balance between proliferation and cell death , 2005, Oncogene.

[145]  B. C. Wong,et al.  Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. , 2005, Gastroenterology.

[146]  K. Chang,et al.  Survivin, a novel anti‐apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[147]  L. Giacomelli,et al.  Survivin expression is significantly higher in pN+ oral and oropharyngeal primary squamous cell carcinomas than in pN0 carcinomas , 2005, Acta oto-laryngologica.

[148]  F. Li,et al.  Role of survivin and its splice variants in tumorigenesis , 2004, British Journal of Cancer.

[149]  H. Stein,et al.  Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. , 2004, Neuroendocrinology.

[150]  I. McNeish,et al.  Survivin: a protein with dual roles in mitosis and apoptosis. , 2005, International review of cytology.

[151]  N. Singh,et al.  Evaluation of Expression of Apoptosis-Related Proteins and Their Correlation with HPV, Telomerase Activity, and Apoptotic Index in Cervical Cancer , 2004, Pathobiology.

[152]  M. P. Holloway,et al.  Aberrant Regulation of Survivin by the RB/E2F Family of Proteins* , 2004, Journal of Biological Chemistry.

[153]  Ru-chih C. Huang,et al.  Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[154]  S. Fulda,et al.  Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol , 2004, Oncogene.

[155]  N. Gale,et al.  Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation , 2004, Histopathology.

[156]  Luc Missotten,et al.  Expression of apoptosis markers in the retinas of human subjects with diabetes. , 2004, Investigative ophthalmology & visual science.

[157]  K. Taira,et al.  Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[158]  M. Daidone,et al.  Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. , 2004, Carcinogenesis.

[159]  K. Hirata,et al.  Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer , 2004, Journal of Translational Medicine.

[160]  S. Florell,et al.  Proliferation, Apoptosis, and Survivin Expression in Keratinocytic Neoplasms and Hyperplasias , 2004, The American Journal of dermatopathology.

[161]  Yuk-Kwan Chen,et al.  Differential expression of p53, p63 and p73 protein and mRNA for DMBA‐induced hamster buccal‐pouch squamous‐cell carcinomas , 2004, International journal of experimental pathology.

[162]  P. Atadja,et al.  Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells , 2004, Cancer Research.

[163]  J. Becker,et al.  HLA‐B35‐restricted immune responses against survivin in cancer patients , 2004, International journal of cancer.

[164]  Fengzhi Li,et al.  Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. , 2004, BioTechniques.

[165]  M. Hermanová,et al.  Prognostic Significance of Anti-apoptosis Proteins Survivin and bcl-2 in Non-small Cell Lung Carcinomas: A Clinicopathologic Study of 102 Cases , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[166]  S. Ansell,et al.  Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma , 2004, Leukemia.

[167]  N. Perkins,et al.  NF-κB: tumor promoter or suppressor? , 2004 .

[168]  Mads Hald Andersen,et al.  Identification of Novel Survivin-Derived CTL Epitopes with Different HLA-A-Restriction Profiles , 2004, Cancer biology & therapy.

[169]  N. Perkins.  NF-kappaB: tumor promoter or suppressor? , 2004, Trends in cell biology.

[170]  John Calvin Reed,et al.  Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res., 9:6523-6533, 2003. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[171]  D. Altieri,et al.  Full-length dominant-negative survivin for cancer immunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[172]  M. Fornaro,et al.  Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway* , 2003, Journal of Biological Chemistry.

[173]  S. Staibano,et al.  Survivin expression in oral squamous cell carcinoma , 2003, British Journal of Cancer.

[174]  M. Yuen,et al.  Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. , 2003, Cancer research.

[175]  W. Sessa,et al.  Regulation of survivin function by Hsp90 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[176]  N. Tanigawa,et al.  [Development of a novel gene therapy using survivin antisense expressing adenoviral vectors]. , 2003, Gan to kagaku ryoho. Cancer & chemotherapy.

[177]  N. Schmitz,et al.  Induction of antitumour immunity using survivin peptide‐pulsed dendritic cells in a murine lymphoma model , 2003, British journal of haematology.

[178]  A. Marchetti,et al.  Survivin gene expression in early‐stage non‐small cell lung cancer , 2003, The Journal of pathology.

[179]  L. Kanz,et al.  Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. , 2003, Blood.

[180]  C. Schamberger,et al.  Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras , 2003, Oncogene.

[181]  Jing Yang,et al.  [Research advances on inhibitor of apoptosis, survivin]. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[182]  David Hardisson,et al.  Molecular pathogenesis of head and neck squamous cell carcinoma , 2003, European Archives of Oto-Rhino-Laryngology.

[183]  Hongxia Zhu,et al.  [Survivin mutants reverse the malignancy of HeLa cells]. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[184]  H. Stein,et al.  Prognostic value of nuclear survivin-expression in esophageal squamous cell carcinoma , 2003 .

[185]  M. Daidone,et al.  Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. , 2003, The Journal of investigative dermatology.

[186]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[187]  Tae Ho Lee,et al.  Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells , 2003, Cancer Gene Therapy.

[188]  M. Janicot,et al.  Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin , 2003, Journal of Pharmacology and Experimental Therapeutics.

[189]  H. Stein,et al.  Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma , 2003, British Journal of Cancer.

[190]  Nicholas J. Hoogenraad,et al.  Molecular Chaperones Hsp90 and Hsp70 Deliver Preproteins to the Mitochondrial Import Receptor Tom70 , 2003, Cell.

[191]  O. Ishiko,et al.  Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix. , 2003, Oncology reports.

[192]  D. Altieri,et al.  Survivin in apoptosis control and cell cycle regulation in cancer. , 2003, Progress in cell cycle research.

[193]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[194]  C. Suschek,et al.  Differential subcellular localization of functionally divergent survivin splice variants , 2002, Cell Death and Differentiation.

[195]  Jian Guan,et al.  [Effects of antisense bcl-2 or survivin on the growth of human neuroblastoma cell line SK-N-MC]. , 2002, Zhonghua yi xue za zhi.

[196]  M. Ikeguchi,et al.  survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma , 2002, British Journal of Cancer.

[197]  M. Daidone,et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer , 2002, Cellular and Molecular Life Sciences CMLS.

[198]  D. Altieri,et al.  A p34(cdc2) survival checkpoint in cancer. , 2002, Cancer cell.

[199]  Yasuo Watanabe,et al.  Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. , 2002, Anticancer research.

[200]  K. Uematsu,et al.  Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. , 2002, Molecular cancer therapeutics.

[201]  K. Kamiguchi,et al.  An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[202]  K. Shroyer,et al.  Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. , 2002, American journal of clinical pathology.

[203]  Alessandra Giodini,et al.  Regulation of microtubule stability and mitotic progression by survivin. , 2002, Cancer research.

[204]  W. R. Bishop,et al.  Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway , 2002, Oncogene.

[205]  B. Boman,et al.  Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. , 2001, Cancer research.

[206]  D. Altieri,et al.  The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.

[207]  G. Krissansen,et al.  Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. , 2001, Journal of the National Cancer Institute.

[208]  J. Li,et al.  Cancer gene therapy using a survivin mutant adenovirus. , 2001, The Journal of clinical investigation.

[209]  B. Wang,et al.  [A novel antiapoptosis gene, survivin, bcl-2, p53 expression in cervical carcinomas]. , 2001, Zhonghua fu chan ke za zhi.

[210]  T. Heinzel,et al.  Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.

[211]  H. Sakamoto,et al.  DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. , 2001, Cancer letters.

[212]  J. Becker,et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.

[213]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[214]  P. Chieffi,et al.  Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. , 2001, Experimental and molecular pathology.

[215]  D. Bartel,et al.  RNA-Catalyzed RNA Polymerization: Accurate and General RNA-Templated Primer Extension , 2001, Science.

[216]  M. Andreeff,et al.  Cytokine-regulated expression of survivin in myeloid leukemia. , 2001, Blood.

[217]  S. Moriyama,et al.  Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy , 2001, International journal of cancer.

[218]  J. Becker,et al.  Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. , 2001, Cancer research.

[219]  R. Weiss,et al.  Urine detection of survivin and diagnosis of bladder cancer. , 2001, JAMA.

[220]  C. Mollinari,et al.  Human Survivin Is a Kinetochore-Associated Passenger Protein , 2000, The Journal of cell biology.

[221]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[222]  D. Vaux,et al.  Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype , 2000, Current Biology.

[223]  H. Rammensee,et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.

[224]  Robert L. Margolis,et al.  Crystal Structure of Human Survivin Reveals a Bow Tie?Shaped Dimer with Two Unusual ?-Helical Extensions , 2000 .

[225]  J. Noel,et al.  Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement , 2000, Nature Structural Biology.

[226]  D. Fabbro,et al.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. , 2000, Cancer research.

[227]  M. Ohira,et al.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma , 2000, Oncogene.

[228]  J. Kleman,et al.  Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. , 2000, Molecular cell.

[229]  J. McNiff,et al.  Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[230]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[231]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[232]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[233]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[234]  S. Schreiber,et al.  Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. , 1997, Current opinion in chemical biology.

[235]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[236]  D. Wilson,et al.  T-cell receptor peptides as immunotherapy for autoimmune disease. , 1997, Critical reviews in immunology.

[237]  K. Flaherty,et al.  Three-dimensional structure of a hammerhead ribozyme , 1994, Nature.